Bal Pharma Limited (BALPHARMA) - Total Assets
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) holds total assets worth Rs3.76 Billion INR (≈ $40.61 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bal Pharma Limited - Total Assets Trend (2006–2026)
This chart illustrates how Bal Pharma Limited's total assets have evolved over time, based on quarterly financial data. Also see Bal Pharma Limited stock valuation for the company's overall valuation and market capitalisation.
Bal Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Bal Pharma Limited's total assets of Rs3.76 Billion consist of 69.8% current assets and 30.2% non-current assets. Review Bal Pharma Limited total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.9% |
| Accounts Receivable | Rs947.98 Million | 25.2% |
| Inventory | Rs1.16 Billion | 31.0% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs134.22 Million | 3.6% |
| Goodwill | Rs38.27 Million | 1.0% |
Asset Composition Trend (2006–2026)
This chart illustrates how Bal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Bal Pharma Limited share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bal Pharma Limited's current assets represent 69.8% of total assets in 2026, an increase from 66.9% in 2006.
- Cash Position: Cash and equivalents constituted 1.9% of total assets in 2026, down from 6.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 31.0% of total assets.
Bal Pharma Limited Competitors by Total Assets
Key competitors of Bal Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Bal Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.05 | 1.07 | 1.08 |
| Quick Ratio | 0.59 | 0.60 | 0.68 |
| Cash Ratio | 0.00 | 0.04 | 0.00 |
| Working Capital | Rs130.06 Million | Rs153.72 Million | Rs116.14 Million |
Bal Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Bal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | Rs3.76 Billion |
| Market Capitalization | $17.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bal Pharma Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bal Pharma Limited's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bal Pharma Limited (2006–2026)
The table below shows the annual total assets of Bal Pharma Limited from 2006 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs3.76 Billion ≈ $40.61 Million |
+11.87% |
| 2025-03-31 | Rs3.36 Billion ≈ $36.30 Million |
+5.06% |
| 2024-03-31 | Rs3.20 Billion ≈ $34.56 Million |
+2.03% |
| 2023-03-31 | Rs3.13 Billion ≈ $33.87 Million |
+20.20% |
| 2022-03-31 | Rs2.61 Billion ≈ $28.18 Million |
+8.52% |
| 2021-03-31 | Rs2.40 Billion ≈ $25.96 Million |
+0.71% |
| 2020-03-31 | Rs2.38 Billion ≈ $25.78 Million |
-8.77% |
| 2019-03-31 | Rs2.61 Billion ≈ $28.26 Million |
+3.77% |
| 2018-03-31 | Rs2.52 Billion ≈ $27.23 Million |
+9.38% |
| 2017-03-31 | Rs2.30 Billion ≈ $24.90 Million |
+9.09% |
| 2016-03-31 | Rs2.11 Billion ≈ $22.82 Million |
+28.78% |
| 2015-03-31 | Rs1.64 Billion ≈ $17.72 Million |
+5.89% |
| 2014-03-31 | Rs1.55 Billion ≈ $16.73 Million |
+3.27% |
| 2013-03-31 | Rs1.50 Billion ≈ $16.20 Million |
+6.14% |
| 2012-03-31 | Rs1.41 Billion ≈ $15.27 Million |
+4.33% |
| 2011-03-31 | Rs1.35 Billion ≈ $14.63 Million |
+8.94% |
| 2010-03-31 | Rs1.24 Billion ≈ $13.43 Million |
+2.19% |
| 2009-03-31 | Rs1.22 Billion ≈ $13.14 Million |
+11.66% |
| 2008-03-31 | Rs1.09 Billion ≈ $11.77 Million |
+20.23% |
| 2007-03-31 | Rs905.28 Million ≈ $9.79 Million |
+2.75% |
| 2006-03-31 | Rs881.03 Million ≈ $9.53 Million |
-- |
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more